Moderna Inc (MRNA)
Drugs • Health Care
May 01, 2026 Moderna Inc. Reports Q1 2026 Financial Results: A Mixed Bag of Growth and Challenges Moderna Inc. reported a significant revenue increase to $389 million in Q1 2026, driven by international COVID vaccine sales, despite a net loss of $1.34 billion. The company faces high operating expenses but is focusing on cost management and strategic partnerships to enhance its market position.
February 20, 2026 Moderna Inc. Reports 2025 Annual Performance: A Year of Challenges and Strategic Growth Moderna's 2025 annual report reveals a revenue drop to $1.9 billion due to reduced COVID-19 vaccine demand, alongside strategic expansions in manufacturing and product development. Despite challenges, the company maintains a robust pipeline and financial flexibility for future growth.
November 06, 2025 Moderna Inc. Reports Q3 2025: Navigating Challenges Amidst a Transformative Landscape Moderna's Q3 2025 report reveals a decline in revenues to $973 million due to reduced COVID-19 vaccine demand, despite significant approvals for its mRNA vaccines. The company is focusing on expanding its therapeutic pipeline and enhancing manufacturing capabilities to navigate a transforming market landscape.
August 01, 2025 Moderna Inc. Reports Q2 2025 Financial Results: Challenges and Innovations in the Pipeline Moderna Inc. has reported a net loss of $825 million for Q2 2025, despite showing improved operational efficiency. The company faces revenue challenges due to decreased COVID-19 vaccination rates, but is actively advancing its vaccine pipeline with several new approvals.
May 01, 2025 Moderna Inc. Reports Q1 2025 Financial Results: Navigating a Transformative Landscape Moderna Inc. reported a revenue decline in Q1 2025, driven by reduced vaccination demand. Despite a net loss, the company aims to diversify its offerings with a strong pipeline in respiratory vaccines and oncology, focusing on cost management for future growth.
February 21, 2025 Moderna Inc.'s 2024 Annual Report: A Year of Transformation and Challenges Moderna Inc.'s 2024 annual report showcases both remarkable product approvals, like mRESVIA, and significant financial challenges, including a drop in COVID vaccine sales. Despite a net loss of $3.56 billion, the company continues to innovate and adapt in the evolving biotech landscape.
February 20, 2025 SWOT Analysis of Moderna Inc. in 2025 This SWOT analysis of Moderna Inc. in 2025 reveals its strengths in mRNA technology and diverse pipeline, while addressing weaknesses and competitive threats. The article highlights growth opportunities in personalized medicine and global vaccine demand, emphasizing the strategic focus needed for sustainable success.
November 07, 2024 Moderna Inc. Reports Q3 2024 Financial Results: A Mixed Bag Amidst Strategic Shifts Moderna's Q3 2024 report shows stable product sales of $1.8 billion, with significant cost reductions and new product approvals, despite facing financial challenges. The company continues to focus on innovation and strategic prioritization to navigate the evolving biopharmaceutical landscape.
August 01, 2024 Moderna Inc. Reports Mixed Results for Q2 2024 Moderna's Q2 2024 report reveals a 30% revenue decline to $241 million, alongside a net loss of $1.27 billion. Despite financial challenges, the company showcases significant advancements in its product pipeline, including promising clinical trial results.
May 02, 2024 Moderna Inc. Reports Significant Decline in Q1 2024 Financial Performance Moderna's Q1 2024 report highlights a dramatic 91% revenue decline to $167 million and a net loss of $1.2 billion. Despite these challenges, the company is focusing on innovation with 47 development programs and cost management strategies to navigate the post-pandemic landscape.